Active immunoprophyilaxis with uromune® decreases the recurrence of urinary tract infections at three and six months after treatment without relevant secondary effects

The clinical impact of bacteremia on outcomes in elderly patients with pyelonephritis or urinary sepsis: A prospective multicenter study

(2018) Arturo Artero et al.   PLoS One

MV140, a sublingual polyvalent bacterial preparation to treat recurrent urinary tract infections, licenses human dendritic cells for generating Th1, Th17 and IL-10 responses via Syk and MyD88

(2016) C Benito-Villalvilla et al.   Mucosal Immunology

Documento de consenso de la Asociación Española de Urología en el manejo de las infecciones del tracto urinario recurrentes no complicadas

(2015) L. Prieto et al.   Actas Urologicas Espanolas

Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics

(2012) M. F. Lorenzo-Gómez et al.   INTERNATIONAL UROGYNECOLOGY JOURNAL

Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis

(2008) Kurt G. Naber et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Etiología de la infección urinaria baja adquirida en la comunidad y resistencia de Escherichia coli a los antimicrobianos de primera línea. Estudio nacional multicéntrico

(2008) Antonia Andreu et al.   MEDICINA CLINICA